Company summary
ValiRx is a life-sciences company focused on early-stage cancer therapeutics and women's health, using evaluation programmes and specialist subsidiaries to advance assets toward licensing.
← Back to the 350
VAL
ValiRx plc
Pharmaceuticals & Biotechnology
- Index
- AIM
- EX-DIVIDEND
- No dividend
- Book status
- 2026 edition — current
Key activities
Preclinical drug evaluation, oncology development, women's-health research, patient-derived cell models through Inaphaea BioLabs and creation or licensing of development vehicles.
Key markets
Biotechnology and pharmaceutical partnering, particularly early-stage oncology, women's health and related drug-development markets.
Key drivers
Successful evaluation programmes, licensing deals, patent protection, partner funding, progress of internal assets and commercial utilisation of Inaphaea's biobank and laboratory capabilities.
Key risks
Preclinical and clinical failure, funding and dilution, no established product revenue, partner dependence, intellectual-property risk and uncertain timing of licensing income.
Recent Developments
FY2025 results showed lower underlying operating costs but continued losses. During 2026 ValiRx raised further capital, exercised an option over an evaluation asset and reported new patent progress, including a Cytolytix patent update in August.
Dividend notes
No dividend; cash is required for research, evaluation programmes and working capital.
The complete 350 Trade Book — 350 leading UK-listed companies, presented in one consistent working reference.
